Company intelligence / Profile preview

Borea Therapeutics

Milan, Milano, Italyboreatherapeutics.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Borea Therapeutics is developing next-generation AAV-based gene therapies that enable targeting of specific tissues and cells. Their platform is designed to increase selectivity and reduce dose requirements, making treatments safer and more effective[2][8][9].

Therapeutic areas: OtherRare Diseases
Modalities: Gene therapyviral vectors (AAV-based)
Industry: Biotech

Partnerships

Collaboration with Scuola Internazionale Superiore di Studi Avanzati (SISSA)[2][8]

Beyond the preview

Go deeper on Borea Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Borea Therapeutics.

Explore the full profile